WASHINGTON — The Senate will vote this week on a key legislative priority for the pharmaceutical industry and the Food and Drug Administration, according to three key senators.
The package spells out how much drug and device makers pay the FDA to fund the agency’s oversight and approval processes, called user fees. The current contracts expire at the end of September, and the agency has said a new agreement is critical to its ability to continue to pay thousands of staffers.
About the Author Reprints
